Codexis/$CDXS
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Codexis
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
Ticker
$CDXS
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
188
ISIN
US1920051067
Website
Codexis Metrics
BasicAdvanced
$233M
-
-$0.97
2.57
-
Price and volume
Market cap
$233M
Beta
2.57
52-week high
$6.01
52-week low
$1.90
Average daily volume
1M
Financial strength
Current ratio
3.723
Quick ratio
3.415
Long term debt to equity
114.014
Total debt to equity
119.884
Interest coverage (TTM)
-17.09%
Profitability
EBITDA (TTM)
-62.063
Gross margin (TTM)
-24.71%
Net profit margin (TTM)
-149.47%
Operating margin (TTM)
-134.40%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
-30.06%
Return on equity (TTM)
-115.53%
Valuation
Price to revenue (TTM)
4.318
Price to book
4.69
Price to tangible book (TTM)
4.94
Price to free cash flow (TTM)
-3.594
Free cash flow yield (TTM)
-27.82%
Free cash flow per share (TTM)
-78.19%
Growth
Revenue change (TTM)
-32.89%
Earnings per share change (TTM)
2.91%
3-year revenue growth (CAGR)
-25.82%
10-year revenue growth (CAGR)
3.58%
3-year earnings per share growth (CAGR)
44.98%
10-year earnings per share growth (CAGR)
7.39%
What the Analysts think about Codexis
Analyst ratings (Buy, Hold, Sell) for Codexis stock.
Codexis Financial Performance
Revenues and expenses
Codexis Earnings Performance
Company profitability
Codexis News
AllArticlesVideos
Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA
GlobeNewsWire·1 month ago
Codexis to Participate in Jefferies Global Healthcare Conference
GlobeNewsWire·1 month ago
Codexis Reports First Quarter 2025 Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Codexis stock?
Codexis (CDXS) has a market cap of $233M as of July 04, 2025.
What is the P/E ratio for Codexis stock?
The price to earnings (P/E) ratio for Codexis (CDXS) stock is 0 as of July 04, 2025.
Does Codexis stock pay dividends?
No, Codexis (CDXS) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Codexis dividend payment date?
Codexis (CDXS) stock does not pay dividends to its shareholders.
What is the beta indicator for Codexis?
Codexis (CDXS) has a beta rating of 2.57. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.